Literature DB >> 24736947

Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer.

Rocky Cipriano1, Kristy L S Miskimen1, Benjamin L Bryson1, Chase R Foy1, Courtney A Bartel1, Mark W Jackson2.   

Abstract

UNLABELLED: FAM83B (family with sequence similarity 83, member B) was recently identified as a novel oncogene involved in activating CRAF/MAPK signaling and driving epithelial cell transformation. FAM83B is one of eight members of a protein family (FAM83) characterized by a highly conserved domain of unknown function (DUF1669), which is necessary and sufficient to drive transformation. Here, it is demonstrated that additional FAM83 members also exhibit oncogenic properties and have significantly elevated levels of expression in multiple human tumor types using a TissueScan Cancer Survey Panel PCR array and database mining. Furthermore, modeling the observed tumor expression of FAM83A, FAM83C, FAM83D, or FAM83E promoted human mammary epithelial cell (HMEC) transformation, which correlated with the ability of each FAM83 member to bind CRAF (RAF1) and promote CRAF membrane localization. Conversely, ablation of FAM83A or FAM83D from breast cancer cells resulted in diminished MAPK signaling with marked suppression of growth in vitro and tumorigenicity in vivo. Importantly, each FAM83 member was determined to be elevated in at least one of 17 distinct tumor types examined, with FAM83A, FAM83B, and FAM83D most frequently overexpressed in several diverse tissue types. Finally, evidence suggests that elevated expression of FAM83 members is associated with elevated tumor grade and decreased overall survival. IMPLICATIONS: FAM83 proteins represent a novel family of oncogenes suitable for the development of cancer therapies aimed at suppressing MAPK signaling. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24736947      PMCID: PMC4135001          DOI: 10.1158/1541-7786.MCR-13-0289

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  18 in total

Review 1.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

2.  The spindle protein CHICA mediates localization of the chromokinesin Kid to the mitotic spindle.

Authors:  Anna Santamaria; Susanna Nagel; Herman H W Sillje; Erich A Nigg
Journal:  Curr Biol       Date:  2008-05-20       Impact factor: 10.834

3.  FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.

Authors:  Sun-Young Lee; Roland Meier; Saori Furuta; Marc E Lenburg; Paraic A Kenny; Ren Xu; Mina J Bissell
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

4.  FAM83B mediates EGFR- and RAS-driven oncogenic transformation.

Authors:  Rocky Cipriano; James Graham; Kristy L S Miskimen; Benjamin L Bryson; Ronald C Bruntz; Sarah A Scott; H Alex Brown; George R Stark; Mark W Jackson
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

Review 5.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

6.  p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.

Authors:  Charlene E Kan; John T Patton; George R Stark; Mark W Jackson
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

7.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

8.  Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Authors:  Justin M Balko; Rebecca S Cook; David B Vaught; María G Kuba; Todd W Miller; Neil E Bhola; Melinda E Sanders; Nara M Granja-Ingram; J Joshua Smith; Ingrid M Meszoely; Janine Salter; Mitch Dowsett; Katherine Stemke-Hale; Ana M González-Angulo; Gordon B Mills; Joseph A Pinto; Henry L Gómez; Carlos L Arteaga
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

9.  FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.

Authors:  Rocky Cipriano; Kristy L S Miskimen; Benjamin L Bryson; Chase R Foy; Courtney A Bartel; Mark W Jackson
Journal:  Oncotarget       Date:  2013-05

10.  Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B.

Authors:  R Cipriano; B L Bryson; K L S Miskimen; C A Bartel; W Hernandez-Sanchez; R C Bruntz; S A Scott; C W Lindsley; H A Brown; M W Jackson
Journal:  Oncogene       Date:  2013-08-05       Impact factor: 9.867

View more
  54 in total

1.  Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Authors:  Hannah Carter; Rachel Marty; Matan Hofree; Andrew M Gross; James Jensen; Kathleen M Fisch; Xingyu Wu; Christopher DeBoever; Eric L Van Nostrand; Yan Song; Emily Wheeler; Jason F Kreisberg; Scott M Lippman; Gene W Yeo; J Silvio Gutkind; Trey Ideker
Journal:  Cancer Discov       Date:  2017-02-10       Impact factor: 39.397

2.  miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma.

Authors:  Yu Mao; Jia Liu; Dakai Zhang; Baosheng Li
Journal:  Tumour Biol       Date:  2016-01-13

3.  Fam83F induces p53 stabilisation and promotes its activity.

Authors:  Mohammed Salama; Diego Benitez-Riquelme; Seham Elabd; Leonel Munoz; Ping Zhang; Matthias Glanemann; Maria Caterina Mione; Robert Goldin; Thierry Soussi; Gary Davidson; Christine Blattner
Journal:  Cell Death Differ       Date:  2019-01-28       Impact factor: 15.828

4.  Genetic Drivers of Pancreatic Islet Function.

Authors:  Mark P Keller; Daniel M Gatti; Kathryn L Schueler; Mary E Rabaglia; Donnie S Stapleton; Petr Simecek; Matthew Vincent; Sadie Allen; Aimee Teo Broman; Rhonda Bacher; Christina Kendziorski; Karl W Broman; Brian S Yandell; Gary A Churchill; Alan D Attie
Journal:  Genetics       Date:  2018-03-22       Impact factor: 4.562

5.  CircMIIP Contributes to Non-Small Cell Lung Cancer Progression by Binding miR-766-5p to Upregulate FAM83A Expression.

Authors:  Tao Wang; Xu Zhu; Kai Wang
Journal:  Lung       Date:  2022-01-11       Impact factor: 2.584

Review 6.  Validation-Based Insertional Mutagenesis (VBIM), A Powerful Forward Genetic Screening Strategy.

Authors:  Sarmishtha De; Ilaria Tamagno; George R Stark; Mark W Jackson
Journal:  Curr Protoc       Date:  2022-03

7.  FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma.

Authors:  Gaoming Wang; Xiaokun Li; Yu Yao; Zhisheng Jiang; Hai Zhou; Kai Xie; Jing Luo; Yi Shen
Journal:  Oncol Lett       Date:  2021-02-17       Impact factor: 2.967

8.  Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma.

Authors:  Weijia Liao; Weilong Liu; Xing Liu; Qing Yuan; Ying Ou; Yao Qi; Wanqiu Huang; Yun Wang; Jian Huang
Journal:  Oncotarget       Date:  2015-09-15

9.  Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression.

Authors:  Yuanyong Wang; Rongjian Xu; Dongyang Zhang; Tong Lu; Wanpeng Yu; Yang Wo; Ao Liu; Tianyi Sui; Jian Cui; Yi Qin; Yanting Dong; Xiaoliang Leng; Dezhi Kong; Wenxing Du; Zhangfeng Huang; Wenhao Su; Tianxiang Yuan; Xiao Sun; Jianxun Wang; Wenjie Jiao
Journal:  Transl Lung Cancer Res       Date:  2019-12

10.  Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.

Authors:  Yoshio Shimizu; Takafumi Tamura; Akira Kemmochi; Yohei Owada; Yusuke Ozawa; Katsuji Hisakura; Takashi Matsuzaka; Hitoshi Shimano; Noriyuki Nakano; Shingo Sakashita; Tatsuya Oda; Nobuhiro Ohkohchi
Journal:  J Gastroenterol Hepatol       Date:  2020-10-05       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.